Logo image of DARE

DARE BIOSCIENCE INC (DARE) Stock Fundamental Analysis

NASDAQ:DARE - Nasdaq - US23666P2002 - Common Stock - Currency: USD

3.17  +0.01 (+0.32%)

Fundamental Rating

2

DARE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of DARE have multiple concerns. DARE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DARE has reported negative net income.
DARE had a negative operating cash flow in the past year.
DARE had negative earnings in each of the past 5 years.
DARE had a negative operating cash flow in each of the past 5 years.
DARE Yearly Net Income VS EBIT VS OCF VS FCFDARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

DARE has a better Return On Assets (-19.96%) than 61.62% of its industry peers.
Industry RankSector Rank
ROA -19.96%
ROE N/A
ROIC N/A
ROA(3y)-93.89%
ROA(5y)-169.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DARE Yearly ROA, ROE, ROICDARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K -2K -4K -6K -8K

1.3 Margins

DARE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DARE Yearly Profit, Operating, Gross MarginsDARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
DARE has less shares outstanding than it did 1 year ago.
DARE has less shares outstanding than it did 5 years ago.
There is no outstanding debt for DARE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DARE Yearly Shares OutstandingDARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
DARE Yearly Total Debt VS Total AssetsDARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

DARE has an Altman-Z score of -16.34. This is a bad value and indicates that DARE is not financially healthy and even has some risk of bankruptcy.
DARE has a Altman-Z score of -16.34. This is amonst the worse of the industry: DARE underperforms 83.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.34
ROIC/WACCN/A
WACC9.77%
DARE Yearly LT Debt VS Equity VS FCFDARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

DARE has a Current Ratio of 1.14. This is a normal value and indicates that DARE is financially healthy and should not expect problems in meeting its short term obligations.
DARE's Current ratio of 1.14 is on the low side compared to the rest of the industry. DARE is outperformed by 83.78% of its industry peers.
DARE has a Quick Ratio of 1.14. This is a normal value and indicates that DARE is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of DARE (1.14) is worse than 77.30% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.14
DARE Yearly Current Assets VS Current LiabilitesDARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

DARE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.54%, which is quite impressive.
Looking at the last year, DARE shows a very strong growth in Revenue. The Revenue has grown by 88.13%.
EPS 1Y (TTM)89.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.07%
Revenue 1Y (TTM)88.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

DARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.33% yearly.
DARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 165.39% yearly.
EPS Next Y86.87%
EPS Next 2Y30.06%
EPS Next 3Y18.55%
EPS Next 5Y31.33%
Revenue Next Year-33.24%
Revenue Next 2Y25.66%
Revenue Next 3Y116.63%
Revenue Next 5Y165.39%

3.3 Evolution

DARE Yearly Revenue VS EstimatesDARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
DARE Yearly EPS VS EstimatesDARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -100 -200 -300 -400 -500

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DARE Price Earnings VS Forward Price EarningsDARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DARE Per share dataDARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as DARE's earnings are expected to grow with 18.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.06%
EPS Next 3Y18.55%

More info and screens

0

5. Dividend

5.1 Amount

DARE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DARE BIOSCIENCE INC

NASDAQ:DARE (2/21/2025, 8:11:55 PM)

3.17

+0.01 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners8.99%
Inst Owner Change-85.86%
Ins Owners1.17%
Ins Owner Change0%
Market Cap27.58M
Analysts80
Price Target21.76 (586.44%)
Short Float %1.02%
Short Ratio2.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-99.86%
Min Revenue beat(2)-100%
Max Revenue beat(2)-99.73%
Revenue beat(4)0
Avg Revenue beat(4)-74.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)-3.57%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-12.68%
EPS NQ rev (3m)-966.66%
EPS NY rev (1m)0%
EPS NY rev (3m)21.64%
Revenue NQ rev (1m)-33.33%
Revenue NQ rev (3m)-36.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-89.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.66
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.22
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.89%
ROA(5y)-169.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1398.08%
Cap/Sales 32.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z -16.34
F-Score5
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)658.06%
Cap/Depr(5y)404.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.07%
EPS Next Y86.87%
EPS Next 2Y30.06%
EPS Next 3Y18.55%
EPS Next 5Y31.33%
Revenue 1Y (TTM)88.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-33.24%
Revenue Next 2Y25.66%
Revenue Next 3Y116.63%
Revenue Next 5Y165.39%
EBIT growth 1Y44.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.76%
OCF growth 3YN/A
OCF growth 5YN/A